New Study Provides Evidence of Success in the Development of New Blood Vessels
In a new study reported in the journal Circulation, scientists are describing the first objective evidence that gene therapy successfully helped patients grow new blood vessels and significantly increased blood flow to heart muscle. The study found that the treatment both improved tissue that had suffered from restricted blood supply and rescued areas of the heart that caused pain even when the patient was at rest.
The study, conducted by researchers at Tufts University School of Medicine and St. Elizabeth's Medical Center, was conducted with 13 patients, all of whom had chronic chest pain and had failed balloon angioplasty, coronary bypass surgery, or both. The patients underwent an imaging exam to determine which areas of the heart were deficient in blood supply and a new cardiac mapping test that can distinguish between normal and blood-starved heart tissue. They were then given injections of DNA for a substance called vascular endothelial growth factor, or VEGF, directly into four sites in the heart muscle where blood supply was blocked or compromised.
Imaging and mapping studies were repeated after sixty days. Each test revealed that, on average, the amount of compromised heart tissue was substantially reduced. Post-treatment tests showed that in five patients, an area of heart muscle that was particularly damaged from lack of blood was completely revived. While these test results are promising, it is likely to be years before researchers know whether gene therapy, or angiogenisism, can predictably promote blood-vessel growth and provide a new tool in treating heart disease. For more information visit wvweb.com/news/JournalCirculation.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.